Rubius Therapeutics (RUBY) is revealing for the first time Tuesday preclinical data to support efforts to transform red blood cells into new types of drugs that attack cancer.
Before today, Rubius was best known for going public with a $2 billion valuation despite zero drugs in clinical trials. There was also that creative re-imagination of its pipeline chart. The results unveiled Tuesday are still from experiments in test tubes and mice, but for Rubius CEO Pablo Cagnoni, they demonstrate that genetically augmenting red blood cells with molecules and proteins to stimulate the immune system is possible.
About the Author Reprints
